Objective To study the effect of rosiglitazone (ROS) on resistin level in patients with type 2 diabetes. Methods 56 patients with type 2 diabetes mellitus were recruited according to WHO criterion(1999). They were randomly divided into two groups, the threatment group 36 and the control group 20 patients. Patients in control group received routine therapy,and patients in treatment group received ROS,4mg/d with routine therapy for 12 weeks. Clinical routine and plasma glucose, insulin and resistin determination were performed. Insulin sensitivity was evaluated using homeostasis model assessment(HOMA) formula. Results Levels of fasting plasma glucose,insulin,HOMA-IR and resistin were significantly decreased. Conclusion ROS can significantly reduce insulin resistance,improve the utilizing of plasma glucose, which has an important effect on level of resistin in patients with type 2 diabete.